Administration of Lycium barbarum polysaccharide (LBP), a new PI3K/AKT/Nrf2 axis activator, prevented the development not only of oxidative stress but also of insulin resistance, as well as of glucose metabolic abnormalities [20–22]. This evidence concerns the gene AKT1 and Insulin resistance.